Solid Tumors

Adjuvant Chemotherapy May Be Spared in Localized Breast Cancer If pCR Is Attained with Neoadjuvant Chemotherapy

Phoebe Starr

April 2019, Vol 10, No 2 - Breast Cancer

San Antonio, TX—Reaching pathologic complete response (pCR) after neo­adjuvant chemotherapy correlates with significantly improved event-free survival (EFS) and overall survival (OS) in patients with localized breast cancer, according to results of a large comprehensive meta-analysis presented at the 2018 San Antonio Breast Cancer Symposium. [ Read More ]

Tamoxifen 5 mg Daily as Effective as 20 mg in Early Localized Breast Cancer

Phoebe Starr

April 2019, Vol 10, No 2 - Breast Cancer

San Antonio, TX—The large, randomized TAM-01 clinical trial demonstrated that 5 mg daily of tamoxifen for 3 years halved the risk for recurrence of breast intraepithelial neoplasia—atypical ductal hyperplasia, ductal carcinoma in situ (DCIS), and lobular carcinoma in situ—in women after surgery and reduced the risk for new contralateral breast cancer by 75% compared with placebo. [ Read More ]

Personalizing Immunotherapy in NSCLC Using PD-L1 and Tumor Mutation Burden as Biomarkers

Wayne Kuznar

April 2019, Vol 10, No 2 - Lung Cancer

San Francisco, CA—Tumor expression of PD-L1 has consistently predicted ­response and survival outcomes in non–small-cell lung cancer (NSCLC), whereas the role of PD-L1 in immune cells is unclear, said Edward B. Garon, MD, Director, Thoracic Oncology Program, David Geffen School of Medicine, University of California, Los Angeles, at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. [ Read More ]

Atezolizumab plus Nab-Paclitaxel for Triple-Negative Breast Cancer with PD-L1 Expression

Phoebe Starr

April 2019, Vol 10, No 2 - Breast Cancer

San Antonio, TX—Adding the PD-L1 inhibitor atezolizumab (Tecentriq) to nab-paclitaxel (Abraxane) chemother­apy is the first immunotherapy-based combination to improve progression-free survival (PFS) and overall survival (OS) in women with advanced or metastatic triple-negative breast cancer and PD-L1 expression compared with placebo plus nab-paclitaxel, according to results of the IMpassion130 clinical trial. [ Read More ]

FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer

Breast Cancer, FDA Approvals, News & Updates, In the News

On April 4, 2019, the US Food and Drug Administration (FDA) expanded the indication of palbociclib (Ibrance; Pfizer), a kinase inhibitor, in combination with specific endocrine therapies for men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This is the first hormonal-based therapy to be approved for men. [ Read More ]

Olaparib Maintenance Extends Progression-Free Survival in Advanced Ovarian Cancer

January/February 2019, Vol 10, No 1 | Payers’ Perspectives In Oncology: ASH 2018 Highlights - In the Literature, Ovarian Cancer

Currently, there are limited therapies to prevent or delay recurrence in advanced ovarian cancer, with approximately 70% of patients having a recurrence within 3 years. The effectiveness of olaparib, an oral poly (ADP-ribose) polymerase inhibitor, in relapsed disease has been well-established; however, its benefit as a maintenance therapy in newly diagnosed advanced ovarian cancer is uncertain. In a recent study, researchers evaluated the efficacy of upfront maintenance therapy with olaparib in patients with newly diagnosed, advanced BRCA-positive ovarian cancer. [ Read More ]